Welcome to our dedicated page for Ocean Biomedical news (Ticker: OCEA), a resource for investors and traders seeking the latest updates and insights on Ocean Biomedical stock.
Ocean Biomedical, Inc. (NASDAQ: OCEA) generates news across biopharma research, intellectual property, strategic partnerships, and corporate developments. As a Providence, Rhode Island-based company focused on oncology, infectious diseases, fibrosis, and malaria, its announcements often highlight progress in preclinical programs and collaborations with academic and industry partners.
Recent news has featured advances in cancer immunotherapy targeting CHI3L1, including bispecific antibodies that combine CHI3L1 inhibition with immune checkpoint targets such as PD1 and CTLA4, as well as research on synergy with tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer. Publications and patent grants related to these technologies, including protection in major markets, are frequent themes.
Ocean Biomedical also issues updates on its malaria platforms, such as patents for PfGARP-targeted antibodies and funding from organizations like the National Institutes of Health and other foundations to support vaccine and therapeutic development. These stories often describe non-human primate studies, exploration of lipid-encapsulated mRNA vaccine approaches, and efforts to address resistance to existing malaria treatments.
Additional news items cover the company’s joint venture with Virion Therapeutics on T cell-based immunotherapies, as well as corporate and listing-related communications, including Nasdaq notices regarding delayed SEC filings. More recently, Ocean Biomedical has announced a strategic expansion into power infrastructure development and a cryptocurrency treasury strategy involving assets such as Bitcoin and Solana, framing this diversification as support for its long-term biopharma mission.
Investors and observers following OCEA news can expect a mix of scientific updates, patent and grant milestones, partnership announcements, and regulatory or listing-related disclosures, reflecting both the company’s research pipeline and its broader corporate strategies.
Ocean Biomedical (NASDAQ: OCEA) announced on May 30, 2024, that it received a notice from Nasdaq regarding the late filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2024. The company is currently not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filings with the SEC. This delay follows previous issues with filing its 10-K for the year ended December 31, 2023.
Nasdaq has required Ocean Biomedical to submit a compliance plan by June 14, 2024, and to file the delinquent Form 10-Q by October 14, 2024. The notice has no immediate impact on the listing or trading of Ocean Biomedical's stock, but further delays could affect its Nasdaq listing. The company aims to file the overdue report as soon as possible.
On May 16, 2024, Ocean Biomedical (NASDAQ: OCEA) announced a new patent for malaria therapeutic antibody discoveries by Dr. Jonathan Kurtis. These antibodies aim to prevent malaria infection and treat severe cases by inducing parasite death via apoptosis during a critical stage of the malaria cycle. This patent adds to Ocean Biomedical's global portfolio, particularly important as malaria strains show resistance to current Artemisinin-based treatments. Ocean is optimizing vaccine and therapeutic antibody formulations before IND submission and clinical trials. Malaria remains a leading cause of death, particularly among children, with 627,000 fatalities in 2022. The new patent strengthens Ocean Biomedical's efforts to address this unmet medical need, leveraging partnerships with top research institutions.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.